Andluca Technologies designs transparent, thin-film power sources that convert ultraviolet light into useful energy at the point of use. These flexible power sources can conform to any shape and disappear into their environment to enable discreet, wireless operation of smart glass. Beyond buildings, our technologies are unlocking new functionalities in the automobile, aviation, military, eyewear, health and IoT sectors. Andluca Technologies was established in 2017 following over 12 years of research on light-responsive films by Professor Lynn Loo and her team at the Organic and Polymer Electronics Laboratory at Princeton University.
Smell loss is an early indicator of infectious and neurodegenerative disorders. In COVID-19, for example, objective smell loss may occur in >90% of patients. Though molecular (PCR) tests are effective in diagnosing SARS-CoV-2 infection, with moderate sensitivity and high specificity, they typically are costly (>$50), with long turnaround times (up to 5-7 days) and have not been as effective in controlling asymptomatic spread. The Aromha Smell Test complements molecular tests with high sensitivity and negative predictive value and can be scaled quickly to provide an important new tool to prevent community spread of COVID, with an at-home, non-invasive, safe, and cost-effective screening test that provides instantaneous results. This platform technology, developed based on 20 years of olfactory research at Harvard, can also be utilized to provide an early signal and improve care in critical neurodegenerative diseases such as Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury.
The logistics of ensuring compliance of thermal profiles (e.g., keeping cold items cold) for each product is a difficult problem. Solutions exist for monitoring temperature at coarse scale (shipping container), but those that precisely track each unit (color-changing stickers), lack the ability to precisely convey information in a scalable manner. Free Dynamics designs electronic temperature sensors that operate without any external batteries for months. Unlike current solutions, our quantum-mechanically-driven sensors are miniature and cost-effective enough to be incorporated into every vial of essential drugs that require stringent storage conditions. As a result, we can assure last-mile compliance while expecting higher accuracy. In addition, we have also shown that our system can be used for authentication which will guard the tagged assets against tampering and counterfeiting.
PrevPanc is developing an improved prophylactic against pancreatitis caused by endoscopic retrograde cholangiopancreatography (ERCP), by targeting two key inflammatory pathways. Post-ERCP pancreatitis can be life-threatening, excruciatingly painful, and costly. PrevPanc is developing a more effective and practical treatment to prevent pancreatitis, with significant improvements beyond current options of indomethacin, stenting, and IV hydration. PrevPanc's therapy is a combination of a calcineurin inhibitor combined with indomethacin to target two distinct inflammatory pathways, achieving higher effectiveness than the current standard of care with minimal change in post-procedure care.
Tandem Repeat Technologies, Inc. (TR Tech) is the market leader in Sustainable Textiles Manufacturing. TR Tech has created the world’s first programable textile which is 100% sustainable, self-healing, and fully biodegradable. Established in 2018, TR Tech has developed revolutionary technology that combines materials science and biomanufacturing to produce performance composites with tunable properties. The technology is covered under five (5) issued US patents and additional five (5) pending with Squitex. The physical characteristics of Squitex will allow it to be adopted into many products and technologies. It is a platform performance material that is renewable, green, strong, flexible, self-healing, energy efficient and friendly to most of today’s manufacturing processes. The use will only be limited by the creativity of application and the ability to produce the quantity of material to meet market demand.
There are over 900k cocaine addicts in the USA alone while worldwide cocaine usage rates have been growing at over 2% a year over the last decade. In the USA this results in over 15k deaths, 505k ER visits and $21B lost annually. Despite all of this, there is currently no FDA approved treatment for cocaine abuse disorder. AddGraft Therapeutics aims to be the first FDA approved treatment for cocaine abuse disorder utilizing our revolutionary gene delivery platform. Our treatment promises to be long lasting, minimally invasive and highly effective at treating the challenging aspects of addiction. AddGraft's technology is a novel skin-based gene delivery platform for treating cocaine abuse. Patients receive an autologous skin graft of genetically modified skin-stem cells which produces a dual molecule solution to effectively break down cocaine, preventing lethal overdose, and to behaviorally prevent frequent use, relapse, and developing of new addictive behaviors.
Genital herpes affects more than 500 million globally and it is incurable. In the US alone, 1 million people are diagnosed every year with herpes. Herpes causes painful viral outbreaks, significant psychological stress, and social stigma. Even though women are more prone to genital herpes, the available prevention option, condoms, is controlled by the male partner. The solution is a new female-controlled product called HerShield, a vaginally applied, soft and flexible pharmaceutical film that has proven safety in two phase I clinical trials, and provides sufficient quantities of drug for protection from herpes. HerShield is designed to be discrete, exceptionally portable, low cost, biodegradable, and easily self-administered without the need for an applicator.
Using patent-pending technology developed at Vanderbilt University, our technique overcomes cost and scaleability limitations associated with traditional manufacturing techniques, while also giving commercial viability to carbon conversion technologies through the introduction of a high-value secondary material produced from greenhouse gas inputs. Our technique relies on electrochemistry, rather than solely catalysis, and results in a highly efficient process to convert atmospheric carbon dioxide into useful functional nanomaterials.
Neurodegenerative diseases are a large group of progressive and eventually fatal diseases of the central nervous system (CNS). These diseases – including Alzheimer’s disease, Parkinson’s diseases, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and Huntington’s disease – are taking an increasingly heavy toll on individuals and the society as the human population ages, yet they remain incurable. Evergreen seeks to develop novel therapies for several neurodegenerative diseases based on AAV-mediated gene transduction.
A Natural Nanoparticle Platform for Drug Delivery to the Brain. Drug delivery to the brain is major challenge because of the existence of the blood brain barrier (BBB). Here we present a novel natural nanoparticle platform that can overcome the BBB and enable efficient drug delivery to the brain. We demonstrate a lead product that is readily translated into clinical applications for effective stroke treatment.
Researchers at Stanford have developed a new water-based disinfectant with the potential to destroy a wide variety of pathogens and significantly improve healthcare settings. AquaROS, a novel and broad-spectrum disinfectant, is based on the formation of micron-sized water droplets that cause the spontaneous generation of highly reactive oxidant species (ROS). Access to safe and effective disinfecting solutions like AquaROS is more critical than ever – in the U.S. approximately the same number of people die from healthcare-associated infections (HAIs) as from AIDS, breast cancer and auto accidents combined. Inexpensively produced by atomizing water, the new disinfectant has been shown to outperform other commercial methods at inactivating Salmonella typhimurium and E. coli. Based on these and other promising results, the researchers anticipate AquaROS can kill bacteria, fungi, mycobacteria and bacterial spores on critical surfaces such as medical instruments.
One of the most worrisome complications of the current global pandemic of COVID-19 is acute respiratory distress syndrome (ARDS), which is characterized by excess inflammation and fluid in the lung and has high mortality despite years of study. Research has indicated that more than 40% of the individuals hospitalized with severe COVID-19 develop ARDS and over half of those cases are fatal. A team of researchers at the University of Minnesota with decades of research knowledge surrounding lung diseases have developed a novel and promising treatment approach for ARDS utilizing Liothyronine (T3), a synthetic form of thyroid hormone that already has FDA approval. Application of T3 to injured lungs has been shown to speed fluid clearance in animal models and clinical trials are already underway to validate translation to humans suffering with ARDS.
We have applied a unique, robust, and comprehensive image-based assay developed in our laboratory to discover small molecule inhibitors of nucleolar function. Results from pilot screens on FDA-approved drugs reveal 83 unique hits that include known and putative antineoplastic agents.
Activating the innate immune system within tumors is a promising new direction in immunotherapy because it can be used against a broad spectrum of tumor subtypes and it ensures that cells throughout the tumor microenvironment become sensitized, resulting in attack and destruction by T cells. RIG-I is a particularly sensitive trigger of innate immune response in tumors, so agonists of this receptor are promising immunotherapy agents. Through a unique class of RIG-I agonists called Stem-Loop RNAs (SLRs), the scientific team is evaluating the efficacy of SLRs as immunotherapy and antiviral agents.
VasoBio is startup company focusing on vascular disease treatment & medical devices. VasoBio has developed a proprietary ligand-based coating technology, VasoCoat, to improve vascular grafts and other blood contacting devices. Our technology overcomes the major barriers of currently available vascular grafts and possesses optimal functionality. The current focus of VasoBio is to apply VasoCoat to improve patency of hemodialysis vascular graft and reduce thrombosis, stenosis, and infection.
EPO-VG are implantable grafts composed of cells which release a steady dose of erythropoietin (EPO) to patients with end stage renal disease. These grafts reduce the cardiovascular risks associated with single dose EPO injections, improving cost and patient outcomes.
VitalCore is a Medical Devices Integration (MDI) solution that provides an integrated platform for showing the status, error messages, and patient info stored across all devices in various hospitals. VitalCore provides a visualized form of status data for easier comprehension and viewership by using tables, bar graphs, line charts, pie charts, and donut charts that enable the users to grasp the trend of the data and generate insights efficiently to improve patient care and reduce costs. Compared to similar device connectivity monitoring providers, VitalCore is focused on medical devices and has an active pilot that provides both an HL7 viewer and mobile application for healthcare professionals on the go. VitalCore is looking to expand their leadership team as they prepare to fundraise.
There are 230 million surgeries performed per year worldwide. Surgical experience is the primary factor dictating outcome of each operation. However, surgical experience is not quantifiable, not accessible as a data source, and not easily distributable between users. This leads to variability in outcomes, complications, inefficiency, and high costs in surgical care delivery. What if an artificial intelligence (AI) platform could be designed that would quantify and learn from surgical experience, then customize and distribute tailored information back to all surgeons in real-time?
Non-invasive, accurate diagnosis and monitoring of prostate cancer through diffusion histology imaging. The technique has been validated with patient samples, demonstrates >95% agreement with pathologist-identified tumor stages, and can distinguish protest cancer from prostatitis or benign prostatic hyperplasia.
The top 5 drugs sold are delivered by injection, 3 are biologics. Due to discoveries in fields like immuno-oncology, more of these high revenue drugs are biologics. Biologic drugs present a big promise, but they are met with a big problem: They are usually macromolecules, a fact that makes their formulations highly viscous and current injection devices require long injection times and larger gauge needles. The net result for patients is pain and discomfort and therefore reduced acceptance and compliance for treatments. AquaDrive (pka Inviscable) is developing a high performance actuator that could drive formulations 7x more viscous than any other technology currently available on the market, reducing the number of injections by half while minimizing device failure due to the robustness of the actuator at the core of the device.
IMIJ Technologies is a startup from the labs of Columbia’s Dr. Scott Small and Dr. Frank Provenzano that focuses on novel approaches to broad neurological and psychiatric screening and diagnostics that can be applied to existing and conventional neuroimaging - structural MRI. IMIJ has successfully developed and adapted technologies initially researched at Columbia to a variety of existing conventional neuroimaging to develop statistically rigorous candidate biomarkers, as well a fully interpretable report detailing the results. IMIJ uses the same images frequently obtained to diagnose brain diseases, images acquired tens of millions of times a year in the US alone. IMIJ's proprietary software requires no additional data or MRI equipment. IMIJ has raised $1.1M seed funding to date and is seeking $9M with the goal of securing approval for indication in order to refine the development and pilot with a major hospital system.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults. IPF is a fatal disease with median survival at 3-5 years. While there exist several clinical approaches to treating IPF, few therapeutics have been clinically proven to provide significant benefits to patients. Eleven P15 is uniquely positioned for early detection and early intervention of IPF. The pivotal discovery of a common polymorphism in the promoter of MUC5B (rs35705950) has been associated with IPF and pulmonary fibrosis associated with rheumatoid arthritis, and this polymorphism increases the production of mucus.
WiLO Networks bridges the gap between passive RFIDs and high power Long Range (LoRa)/Sigfox to enable precision agriculture, military surveillance, fire mitigation, smart highways, and other IoT applications. Currently, WiLO Networks focus is to provide solutions for precision agriculture. WiLO Networks is building a novel physical layer communication technology based on low-power integrated circuits (ICs), which can be embedded in sensor nodes and gateways at very low cost. This physical layer technology combined with novel network architecture and protocols, as well as intelligent machine learning techniques promises a 10 year lifetime for sensor nodes powered on millimeter-scale batteries. These ultra-low power sensor networks are the key to precision agriculture, monitoring the health of buildings/bridges, and military surveillance. WiLO's solutions can reduce waste to promote sustainability and carbon neutrality.
Each year millions of people suffer from symptoms of sore throat, laryngitis and cough due to colds and inflammation of the upper aerodigestive tract. Current methods of treatment are suboptimal and rely primarily on throat gargles, sprays, and lozenges, which treat only the mouth and part of the upper throat. They completely miss 50% of the inflamed area. This product is an OTC inhaled liquid mist that is inexpensive, portable, disposable, natural, tastes good, and is more effective because it treats the entire upper aerodigestive tract. The target market would be everyday people with cough, voice and sore throat complaints, as well as singers and voice professionals.
Cancer drug efficacy is limited by dosage restructions based on side effects of cancer drugs on healthy cells. Targeting drugs to tumors specifically can substantially improve the efficacy of existing drugs, and reduce the unpleasant side effects of cancer treatment. Cytosolix is using the high acidity characteristic of tumors to preferentially target drugs to these cells. The platform is applicable to 95% of cancers and 90% of those therapies, giving Cytosolix the opportunity to revolutionize drug design in oncology.
While deep learning methods exist to guide protein optimization, examples of novel proteins generated with these techniques require a priori mutational data. Aperiam is taking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry. We have trained a portfolio of computer vision algorithms on protein chemistry and use those algorithms to mutate genes for improved catalysis, expression, stability, and solubility. We are now using this approach to build our own suite of stabilized and solubilized enzyme therapeutics for direct delivery to the lung via nebulization and in parallel tailoring the computer vision framework to antibodies for expedited development and improved manufacturability.
With over 2/3 of the US population being overweight, and serious and deadly effects associated with obesity, a treatment which prevents and cures obesity is essential. However, previously tested obesity drugs have been characterized by low tolerability and serious side effects. This treatment uses LCN2, a natural appetite-suppressing hormone to treat obesity without the side effects.
The labyrinth of jumbled blood vessels in the microenvironment of a solid tumor remains one of the toughest blockades for cellular therapies to penetrate and treat. For example, glioblastoma (GBM), the most common and aggressive type of brain cancer diagnosed in more than 22,000 Americans every year, is known for its prominent and abnormal vascularity and being immunologically "cold." Radix Therapeutics is developing immunotherapies to eradicate solid tumor cancers by targeting the tumor stroma, bridging the gap between current immunotherapies and drug-resistant cancers. Radix's improved immunotherapy combines chimeric antigen receptor (CAR) T cell therapy with selective inhibitors, enabling engineered cells to punch their way through and attack the tumor. Proof of concept has shown significantly enhanced survival in mice.
As part of a portfolio of COVID-19 inspired innovations aimed at advancing RNA vaccines and tools, Stanford researchers have developed a secured, invite-only version of their popular Eterna platform for designing mRNA vaccines. Eterna is an online application that integrates RNA folding algorithms, a video game interface, and associated computational methods to revolutionize vaccine design and RNA structure prediction. The new, secured version of the platform (called EteRNA Enterprise) is able to host selected participants to work in a confidential manner on problems such as designing improved mRNA vaccines that can be translated to clinical trials by industry partners and other collaborators. The data and designs generated by Eterna users may be used to develop improved mRNA vaccines immediately for the COVID-19 pandemic.
Airviz works with Fortune 500 companies who are typically struggling with air quality problems in safety, employee wellness, product quality control, and decreased manufacturing yield. Air quality sensing is a $240MM market, with a 14.3% CADR above $500 M by 2024. There is a global, growing need for affordable sensor networks in homes, office spaces, urban and rural communities to capture actionable air quality data and predictions. Airviz builds air quality sensors and sensor networks, including 24/7 pollution mapping and real-time alerts to help decrease regulatory fines, increase yield, improve safety metrics, and address employee wellness for low-turnover and high satisfaction. Many of the air quality sensors on the market now do not have IoT capability and require a safety engineer to walk around and spot check air pollution with expensive instruments. With our smart calibration techniques, managers can use automated air quality sensor networks that give smart, actionable information and help save money.
Cache is a MIT startup from Prof. Mark Bathe’s lab seeking seed funding and entrepreneurs to help lead the next phase of customer discovery/hypothesis validation. Their technology enables massive and low-energy storage, up to millennium timescales, and random access of nucleic acid samples from a broad array of sources including viral, bacterial, mammalian, and synthetic for biological banking, molecular surveillance, ecological preservation, or massive archival data storage. They are seeking a passionate, adventurous, and creative entrepreneur to join their early-stage venture to help launch this technology into the 21st-century biotechnology space, and seed funding to catalyze the start-up. Their immediate aim is to recruit an entrepreneur who will be excited to mature their business plan using market discovery and research on product-market fit. They are ready to test the market’s appetite for this technology, developing partnerships along the way.
GenoTwin is a next-generation genomics platform that combines leading genomics expertise with data science to transform the detection of pathogens and our understanding of individual immune responses to them. We envision a future where data-rich pathogen and immuno-surveillance are a part of the public health fabric, ushering in an era of precision medicine and enlightened policy-making. Specifically, we have developed an innovative genomics platform that combines cutting-edge capabilities in genomics, artificial intelligence, and bioinformatics to support clinicians, public health officials, and researchers. Out solutions encompass four key areas: ) Pathogen detection, 2) Pathogen surveillance, 3) Immune/resistance assessment, and 4) Precision treatment development. We were founded by leaders in this field and are supported by a Scientific Advisory Board of widely esteemed scientists and practitioners in genomics, virology, infectious disease, and epidemiology.
Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of MYC is virtually unmatched, making MYC one of the most frequently deregulated oncogenes in human tumors, including, liver, kidney, CNS, hematopoietic, breast, prostate, lung and GI tumors. Human studies and animal models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers. Our founders, Drs. Gouw and Felsher, discovered that MYC regulates the aberrant lipid metabolism of tumors and that inactivation of key lipid enzymes results in regression of tumors.
The Synaural platform uses engineered acoustic probes to elicit specific neural activity within the brain. A robust, easy to use, non-invasive headset records the neural activity and patented algorithms extract unique metrics that provide objective insight to the subject’s neural health and can be used to guide treatment in a meaningful, measured way. To date, the metrics have demonstrated enough specificity to be correlated with various conditions e.g. concussion, learning disabilities (e.g. Autism, reading, dyslexia), and hearing.
Foodborne illness is a significant health and economic problem globally. Cross-contamination of food by pathogens via surfaces of food processing equipment is a leading risk factor in foodborne disease outbreaks. Antimicrobial coatings that make food contact surfaces self-sanitizing have potential to reduce cross-contamination and represent a $2.3B market opportunity. Despite that promise, the antimicrobial coating technology available for food contact surface applications is severely limited by a lack of food-grade coatings, lack of efficacy in high volume/organic matter environments, difficult application, high cost and challenges in use with legacy equipment. We have developed novel antimicrobial coatings to make food contact surfaces self-sanitizing to prevent cross-contamination. The coatings are made of food-grade, FDA GRAS materials. They are safe, effective, low-cost, environmentally friendly and useable on legacy equipment. The underlying technology was developed at University of California-Davis.
Palm Therapeutics is a San Diego based biotechnology startup, and member of JLABS@San Diego, in the early stages of development of an innovative class of drugs known as depalmitoylating molecules (DPALMs). The DPALM strategy was developed in the Devaraj Lab at The University of California San Diego by Dr. Andrew Rudd and Prof. Neal Devaraj. Our technology targets post-translational protein palmitoylation and represents a fundamentally new approach to inhibiting protein function. In preliminary studies, NRas-targeted DPALMs have shown in vitro and in vivo efficacy in NRas-driven melanoma models, and in September 2020, we were awarded a Phase I SBIR from NIH/NCI to pursue this indication.
Therapeutics for Fatty Acid Oxidation Disorders. EnergXTherapeutics is developing a platform of drug products that provides comprehensive treatment solutions that targets the biochemical defects induced by deficiency of enzymes/proteins that participates in the mitochondrial long chain fatty acid oxidation (FAO) pathway reactions. Broad IP claims are issued, with more pending, that puts this team in a strong position to utilize its products platform for treating several FAO diseases.
Over 95% of rare disease have no treatment or cure: there are over 7,000 known rare diseases collectively affectiting 30 million Americans. Many of these disease are genetic disorders, in which there can be considerable genetic variation between patients. Current drug development pipeline does not cater to rare mutations, as drug development often takes more than 10 years and over $2B to get a drug to market, making the small patient populations inhibiting. Even if a therapy is developed, genetic variation of the disease means not all patients in the already-small patient population may be able to be treated, limiting their impact and incentive to develop these therapies.
Little is known about how engineered CAR-T cells move through the body and proliferate after they are first removed, altered, expanded in number and, finally, returned to a patient's body. Vellum Biosciences has developed a way to genetically tag CAR T cells that enables them to be imaged via positron emission tomography (PET) scan in combination with a radiotracer specific to that tag.
Gold mining has been a historically low innovation industry. The industry standard is to use a cyanide process to isolate gold, which is expensive and potentially dangerous. Cycladex has created a method to isolate gold in an inexpensive, environmentally-friendly way.
Exotanium is a startup created by two professors and one graduated Ph.D. student from the Department of Computer Science at Cornell University. Exotanium is developing a new cloud-native application container platform that improves performance, security, and cost for both public and private clouds. The technology is based on cutting-edge research and is patent-protected. Exotanium recently won a Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) and is actively raising more investments. The company is located in Ithaca, NY.
GlimmerX has developed a fast, robust point-of-care diagnostic development platform based on glycoconjugate immunochemistry for common infectious diseases, such as leptospirosis, sepsis, UTI and meningitis that is better than current technologies. To establish proof of principle for our platform, we focus on glycans in leptospirosis, which has a large unmet US and global diagnostics need for veterinary and human disease. In a pilot project, Blavatnik funds would be used for PCT fees, and CRO costs for GLP antigen production, monoclonal antibody production and animal experiments to validate our approach, and they would leverage CT Innovations matching funds and SBIR funding.
Viral infections causing hepatitis are major contributors to human morbidity and mortality. Currently, there are no approved directly acting antivirals that cure two of these viruses - hepatitis B (HBV) and E viruses (HEV) – that account for close to 300 million infections world-wide. Our goal is to develop novel small molecule therapeutics that can be readily deployed to combat efficiently these diseases. To achieve this, we capitalize on discoveries and technical advances from our lab that put us in a unique position for targeted high through-put screens. We have already identified a lead molecule that is effective against multiple HEV genotypes, and we have uncovered a minimal set of host factors that are essential for HBV persistence.
KneeMo addresses problems associated with musculoskeletal disorders including sports related injuries and chronic disease such as osteoarthritis (OA). The potential market is substantial since musculoskeletal disorders affect more than one out of every two persons in the United States over age 18 and three out of four over age 65. Osteoarthritis alone accounts for 242 million people in the world who live with activity limiting symptoms. Pharmaceuticals, often used to alleviate the musculoskeletal pain come with side effects that can include addiction. KneeMo takes a novel mechanical approach to engage multimodal sensory pathways that signal pain using cutaneous mechanical stimuli (e.g., vibration) where over stimulation in one mode of the system (e.g., vibration) can gate response in other modalities (e.g. pain). KneeMo was shown in a placebo controlled clinical trial to provide an effective and safe alternative to pharmacological interventions to reduce pain and enhance function.
Moving Therapeutic Proteins Into the Cytosol and Nucleus. Exolva is using CPMPs (cell-permeant miniature proteins) to deliver therapeutic enzymes and gene-editing tools to correct inborn genetic disease. CPMPs are small, folded proteins that contain a specific array of five Arg residues on an ⍺-helix backbone. CPMPs can reach cytosol and nucleus with efficiencies as high as 75%. CPMPs possess many advantages relative to previous, purported ‘cell-penetrating peptides’, including low toxicity, high and tunable stability, enzyme cargo retains enzymatic activity, among other features.
The vast majority, 95%, of drugs developed by companies to treat pancreatic cancer do not end up being approved. Vesselon's strategy for developing cancer therapies is not by finding new drugs, but by increasing the efficacy of existing approved drugs for cancer, starting with pancreatic cancer.
Knee cartilage injuries in young active people have unique challenges that do not face older patients. The treatments need to be able to withstand intense activity and last for years. There is currently no gold standard treatment, with all solutions having significant drawbacks in price, recovery time, and/or longevity of treatment. Nanochon has developed a 3D printed synthetic cartilage replacement which is inserted with minimally invasive surgery and encourages new tissue growth, extending the lifetime of the treatment.
LEAH Labs is the first in the world using gene-editing to make a cure for cancer in dogs. We're building the first cure for canine cancer. It's called CAR-T cell therapy, and we know it works. CAR-T cells are FDA-approved and already saving human patients from their deathbeds in clinics today. This advance can only be made affordable for dogs because of our company's expertise in gene-editing technology.
Velox Biosystems plans to develop and launch a rapid diagnostic product for urinary tract infections (UTI), a problem that affects nearly 50 percent of the population at least once in their lifetime. This decision follows the startup’s completion of a recent clinical feasibility test that yielded impactful clinical data for the company to move forward with the next steps in development. Velox Biosystems has created an ultra sensitive rapid detection system that provides for no or minimal sample processing, high throughput scanning of large sample volumes, with single target sensitivity and unprecedented speeds. Utilizing a digital droplet molecular detection platform, we are developing a point of care diagnostic device to address critical unmet needs in the UTI, liquid biopsy, and sepsis spaces. Total available market of over $1 Billion.
ClaraSim Systems, Inc. has developed a computer simulated environment in which surgeons can perform surgery on virtual bone using virtual instruments. By combining patient-specific data with a powerful simulation engine, we are able to create 3-D patient models that can be explored and modified in real-time with virtual surgical tools providing both haptic and visual feedback. Our system enhances the surgeon's ability to perform skilled surgery by enabling them to rehearse drilling through accurate representations of the patient's bony and fragile structures. The anatomical insight gained from interacting with the simulation provides guidance during actual surgery leading to better outcomes. While the system enables preoperative rehearsal, it is also used as a teaching tool, giving trainees the opportunity to experience many different cases in a safe and efficient setting. The technological and clinical capabilities of the product stem from over 30 person-years of research conducted by the company founders.